Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3. Estimated liver parasite load on day 6

Published byGladys Nelson Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3. Estimated liver parasite load on day 6"— Presentation transcript:

1 Figure 3. Estimated liver parasite load on day 6
Figure 3. Estimated liver parasite load on day 6.5, with 95% confidence intervals, plotted by volunteer. Volunteers are grouped according to vaccine and ordered according to liver burden. Groups are ordered according to efficacy (significant delay to parasitemia by blood-film data). The dashed horizontal line marks the average liver burden for control subjects. D, DNA expressing malaria epitope-thrombospondin-related adhesion protein (ME-TRAP); F, attenuated fowlpox strain FP9 expressing ME-TRAP; ICC-1132, a hepatitis B core-based circumsporozoite vaccine; M, modified virus Ankara (MVA) expressing ME-TRAP; R, particulate vaccine RTS,S/AS02 encoding most of the circumsporozoite protein. M appearing in regimens with RTS,S/AS02 denotes MVA expressing the circumsporozoite protein. From: Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites J Infect Dis. 2005;191(4): doi: /427243 J Infect Dis | © 2005 by the Infectious Diseases Society of America

2 Figure 4. Growth rates, with 95% confidence intervals, plotted by volunteer. Volunteers are grouped according to vaccine and ordered according to growth rate. The dashed horizontal line marks the average growth rate. D, DNA expressing malaria epitope-thrombospondin–related adhesion protein (ME-TRAP); F, attenuated fowlpox strain FP9 expressing ME-TRAP; ICC-1132, a hepatitis B core-based circumsporozoite vaccine; M, modified virus Ankara (MVA) expressing ME-TRAP; R, particulate vaccine RTS,S/AS02 encoding most of the circumsporozoite protein. M appearing in regimens with RTS,S/AS02 denotes MVA expressing the circumsporozoite protein. From: Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites J Infect Dis. 2005;191(4): doi: /427243 J Infect Dis | © 2005 by the Infectious Diseases Society of America

3 Figure 5. Comparison of estimates for liver burden by different modeling strategies. D, DNA expressing malaria epitope-thrombospondin–related adhesion protein (ME-TRAP); F, attenuated fowlpox strain FP9 expressing ME-TRAP; ICC-1132, a hepatitis B core–based circumsporozoite vaccine; M, modified virus Ankara (MVA) expressing ME-TRAP; R, particulate vaccine RTS,S/AS02 encoding most of the circumsporozoite protein. M appearing in regimens with RTS,S/AS02 denotes MVA expressing the circumsporozoite protein. From: Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites J Infect Dis. 2005;191(4): doi: /427243 J Infect Dis | © 2005 by the Infectious Diseases Society of America

4 Figure 6. Schema relating sporozoite inoculum, initial merozoite release, multiplication rate, and diagnosis by blood-film examination From: Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites J Infect Dis. 2005;191(4): doi: /427243 J Infect Dis | © 2005 by the Infectious Diseases Society of America

5 Figure 1. Example of line fit by individual sine wave modeling approach. Volunteer 184 received FP9 followed by modified virus Ankara expressing the malaria epitope-thrombospondin-related adhesion protein and became positive, by blood-film examination, on day 11. The line drawn here was determined by log(P) = 0.56t sin(πt ). PCR, polymerase chain reaction. From: Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites J Infect Dis. 2005;191(4): doi: /427243 J Infect Dis | © 2005 by the Infectious Diseases Society of America

6 Figure 2. r<sup>2</sup> values for line fit, by individual sine wave modeling
From: Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites J Infect Dis. 2005;191(4): doi: /427243 J Infect Dis | © 2005 by the Infectious Diseases Society of America

7 Table 1. Summary of vaccination regimens, nos
Table 1. Summary of vaccination regimens, nos. of volunteers with polymerase chain reaction (PCR) data available, and efficacy determined by use of blood-film data. From: Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites J Infect Dis. 2005;191(4): doi: /427243 J Infect Dis | © 2005 by the Infectious Diseases Society of America

Download ppt "Figure 3. Estimated liver parasite load on day 6"

Similar presentations

Up date on malaria vaccine

Up date on malaria vaccine
Date of download: 9/17/2016 From: Polymerase Chain Reaction for the Diagnosis of HIV Infection in Adults: A Meta-Analysis with Recommendations for Clinical.

Date of download: 9/17/2016 From: Polymerase Chain Reaction for the Diagnosis of HIV Infection in Adults: A Meta-Analysis with Recommendations for Clinical.
From: Hepatitis B Virus Strains with Mutations in the Core Promoter in Patients with Fulminant Hepatitis Ann Intern Med. 1995;122(4):241-248. doi:10.7326/0003-4819-122-4-199502150-00001.

From: Hepatitis B Virus Strains with Mutations in the Core Promoter in Patients with Fulminant Hepatitis Ann Intern Med. 1995;122(4): doi: /
department < clinical chemistry, microbiology and immunology >

department < clinical chemistry, microbiology and immunology >
Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.
Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Fig. Parasitemia detected by PCR

Fig. Parasitemia detected by PCR
Table 1. Baseline Characteristics of the 36,636 Study Subjects

Table 1. Baseline Characteristics of the 36,636 Study Subjects
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.

Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.
Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.
Table 1 Characteristics of the 968 Women in the Study Group

Table 1 Characteristics of the 968 Women in the Study Group
Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.
Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.
From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

From: Unmasking Masks in Makkah: Preventing Influenza at Hajj
From: Clinical and Laboratory Diagnosis of Dengue Virus Infection

From: Clinical and Laboratory Diagnosis of Dengue Virus Infection
From: Rotarix: A Rotavirus Vaccine for the World

From: Rotarix: A Rotavirus Vaccine for the World
Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Similar presentations

Ads by Google